MediWound Ltd./$MDWD
1D1W1MYTD1Y5YMAX
About MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
- Ticker
- $MDWD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 121
- Headquarters
- Yavne, Israel
- Website
- www.mediwound.com
MediWound Ltd. Metrics
BasicAdvanced
$169M
-
-$2.25
0.16
-
Price and volume
Market cap
$169M
Beta
0.16
52-week high
$20.30
52-week low
$13.06
Average daily volume
66K
Financial strength
Current ratio
2.316
Quick ratio
2.094
Long term debt to equity
24.142
Total debt to equity
24.142
Profitability
EBITDA (TTM)
-30.749
Gross margin (TTM)
15.46%
Net profit margin (TTM)
-170.10%
Operating margin (TTM)
-267.75%
Effective tax rate (TTM)
-0.71%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-28.59%
Return on equity (TTM)
-72.37%
Valuation
Price to revenue (TTM)
13.708
Price to book
4.75
Price to tangible book (TTM)
4.75
Price to free cash flow (TTM)
-5.7
Free cash flow yield (TTM)
-17.54%
Free cash flow per share (TTM)
-2.301
Growth
Revenue change (TTM)
-40.26%
Earnings per share change (TTM)
-14.61%
3-year revenue growth (CAGR)
-23.01%
10-year revenue growth (CAGR)
28.33%
3-year earnings per share growth (CAGR)
3.72%
10-year earnings per share growth (CAGR)
-11.16%
MediWound Ltd. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.